Oct 24 (Reuters) - Boston Scientific Corp reported a narrower third-quarter loss, with sales of its array of medical devices unchanged from the year-ago period.
The company said on Thursday it lost $5 million, or nil per share, in the third quarter. That compared with a net loss of $664 million, or 48 cents per share, in the year-earlier period, when the company took restructuring and litigation charges.
Global company sales of $1.735 billion matched Wall Street expectations. Boston Scientific said sales would have risen 4 percent, excluding divested businesses and the impact of the stronger dollar, which lowers the value of sales in overseas markets.
The company forecast full-year earnings, excluding special items, of 69 cents to 71 cents per share. It had previously forecast 67 to 71 cents per share.